Intravenous iron in chronic kidney disease: Haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin

Journal of Renal Care

Volumn 34, Issue 3, 2008, Pages 112-115

  Tagboto, Senyo ^a   Cropper, Liz ^a   Mostafa, Samiul ^a   Turner, June ^a   Bailey, Georgina ^a   Pugh Clarke, Karen ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Anaemia; Chronic kidney disease; Ferritin; Haemoglobin; Intravenous Iron Fluids; Venofer

Indexed keywords

ERYTHROPOIETIN; FERRIC ION; FERRITIN; HEMOGLOBIN; IRON(III) HYDROXIDE SUCROSE COMPLEX; IRON(III)-HYDROXIDE SUCROSE COMPLEX; SUCROSE; TRANSFERRIN;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG EFFECT; DRUG MONITORING; ECONOMICS; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; FERRITINS; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; SUCROSE; TRANSFERRIN; TREATMENT OUTCOME;

EID: 50449109604     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2008.00026.x     Document Type: Article

References (11)

1. Kuriyama S., Tomonari H., Yoshida H. et al. (1997). Reversal of anaemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron 77, 176-185.
2. Levey A.S., Coresh J., Greene T. et al., for the Chronic Kidney Disease Epidemiology Collaboration. (2006). Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of Internal Medicine 145, 247-254.
3. Levin A., Singer J., Thompson C.R. et al. (1996). Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. American Journal of Kidney Diseases 27, 347-354.
4. Macdougall I.C., Hutton R.D., Cavill J. et al. (1989). Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. British Medical Journal 299, 157-158.
5. Macdougall I.C., Tucker B., Thompson J. et al. (1993). A randomized controlled study of iron supplementation in patients treated with erythropoietin. Journal of the American Society of Nephrology 4, 428.
6. Mircescu G., Gameata L., Capusa C. et al. (2006). Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrology Dialysis Transplantation 21, 120-124.
7. Silverberg D.S., Iaina A., Peer G. et al. (1996). Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis. American Journal of Kidney Diseases 27, 234-238.
8. Silverberg D.S., Blum M., Agbaria Z. et al. (1999). Intravenous iron for the treatment of predialysis anaemia. Kidney International 55, S79-S85.
9. Silverberg D.S., Blum M., Agbaria Z. et al. (2001). The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anaemia of chronic renal failure in the predialysis period. Clinical Nephrology 55, 212-219.
10. Stoves J., Inglis H. & Newstead C.G. (2001). A randomised study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation 16, 967-974.
11. Sunder-Plasmann G. & Horl W.H. (1994). Iron metabolism and iron substitution during erythropoietin therapy. Clinical Investigation 72, S11-S15.